Hippocratic oath for pharma industry? šŸ“˜āœ‹

March 25, 2018

Pfizer just got burned, brain scanner in a helmet, BBC constructed a virtual flu pandemic across the UK and other interesting reads from the past week. 

General

  • Chinese pharma companies are stepping up their push into the US generics market. Link

  • China plans a "zero" tariff for cancer drugs. Link

  • What's more prescribed than opioids? Weirdly, a thyroid drug. Link

  • Novartis teams up with Harvard to develop next-gen biomaterial systems to deliver immunotherapies. Link

  • New FDA transparency push begins with J&J's Erleada. Link

  • Britain's use of biosimilars takes off while the U.S. lags. Link

  • Lundbeck to acquire Prexton ā€“ a deal valued up to ā‚¬905 million. Link

  • Daiichi taps Hitachi for regenerative medicine manufacturing. Link

  • GSK pulls out of $20 billion race for Pfizer's consumer health-care business. Link

Digital Health

  • Tooth sensor measures intake of sugar, salt, alcohol. Link

  • AI can spot signs of Alzheimerā€™s before your family does. Link

Research

  • A patch developed from stem cells has been used to treat age-related macular degeneration. Link

  • AI for drug discovery in two stories. Link

  • Scientists develop brain scanner in a helmet. Link

Perspective and Opinions

  • Drug executives should take a Hippocratic oath. Link

  • Is Boston biotech in a bubble? Link

  • Regulatory alignment with the EMA must continue after Brexit to avoid disruption to the supply chain. Link

Interesting

  • BBC constructed a virtual flu pandemic across the UK. Link

  • Hip-hop can help kids, parents spot strokes and act fast. Link

  • Why are female condoms so hard to find? šŸ‘‡

Startups of the Week

Unity Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. Closed a $55m Series C financing.

twoXAR uses its proprietary AI-driven platform to rapidly identify drug candidates for in vivo testing in weeks (rather than years) across therapeutic areas including diseases such as liver cancer, rheumatoid arthritis, and type 2 diabetes. Raised $10m in Series A financing.